DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Harrell Investment Partners LLC

Harrell Investment Partners LLC decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 32.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,613 shares of the medical device company’s stock after selling 1,703 shares during the quarter. Harrell Investment Partners LLC’s holdings in DexCom were worth $247,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of DXCM. Private Trust Co. NA grew its position in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of DexCom during the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC boosted its stake in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Robert W. Baird reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Finally, Barclays increased their target price on DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.50.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $81.01 on Thursday. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.27. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The business’s fifty day moving average price is $79.53 and its two-hundred day moving average price is $79.39. The firm has a market capitalization of $31.76 billion, a PE ratio of 60.46, a P/E/G ratio of 1.75 and a beta of 1.46.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business earned $0.32 earnings per share. DexCom’s quarterly revenue was up 12.5% on a year-over-year basis. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other news, Director Nicholas Augustinos sold 2,618 shares of the firm’s stock in a transaction on Friday, June 13th. The stock was sold at an average price of $81.69, for a total transaction of $213,864.42. Following the transaction, the director now directly owns 37,083 shares of the company’s stock, valued at approximately $3,029,310.27. This trade represents a 6.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the firm’s stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares in the company, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,724 shares of company stock valued at $2,157,034 over the last three months. Company insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.